Abeona Therapeutics Inc. (ABEO) and Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Contrasting side by side

Abeona Therapeutics Inc. (NASDAQ:ABEO) and Phio Pharmaceuticals Corp. (NASDAQ:PHIO) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics Inc. 3 0.00 25.42M -1.36 0.00
Phio Pharmaceuticals Corp. N/A 0.00 25.07M -1.01 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Abeona Therapeutics Inc. and Phio Pharmaceuticals Corp.

Profitability

Table 2 shows Abeona Therapeutics Inc. and Phio Pharmaceuticals Corp.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics Inc. 1,002,247,368.21% 0% 0%
Phio Pharmaceuticals Corp. 7,636,308,254.65% -95.7% -74.6%

Risk & Volatility

Abeona Therapeutics Inc. has a 1.84 beta, while its volatility is 84.00% which is more volatile than Standard & Poor’s 500. In other hand, Phio Pharmaceuticals Corp. has beta of 1.82 which is 82.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio of Abeona Therapeutics Inc. is 3.3 while its Quick Ratio stands at 3.3. The Current Ratio of rival Phio Pharmaceuticals Corp. is 8.5 and its Quick Ratio is has 8.5. Phio Pharmaceuticals Corp. is better equipped to clear short and long-term obligations than Abeona Therapeutics Inc.

Analyst Recommendations

Abeona Therapeutics Inc. and Phio Pharmaceuticals Corp. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Abeona Therapeutics Inc. 0 1 2 2.67
Phio Pharmaceuticals Corp. 0 0 0 0.00

Abeona Therapeutics Inc.’s upside potential is 401.22% at a $12.33 average target price.

Institutional & Insider Ownership

Abeona Therapeutics Inc. and Phio Pharmaceuticals Corp. has shares owned by institutional investors as follows: 64.4% and 10.9%. 0.3% are Abeona Therapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 5.9% of Phio Pharmaceuticals Corp.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Abeona Therapeutics Inc. -30% -45.7% -66.45% -60.7% -81.09% -63.73%
Phio Pharmaceuticals Corp. 2.34% 2.63% -17.02% 9.24% -72.54% 18.22%

For the past year Abeona Therapeutics Inc. has -63.73% weaker performance while Phio Pharmaceuticals Corp. has 18.22% stronger performance.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companyÂ’s lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.